Cell Death & Disease-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2024-03-30 ms3000002118315862 来自广东省

偏重的研究方向：免疫;细胞死亡
经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗

10 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2022-12-30 148b8e1fm60暂无昵称

投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？

57 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2023-08-25 1245a556m23暂无昵称来自河南省

从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？

73 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2024-01-16 ms4000000731438466 来自天津

偏重的研究方向：肿瘤
经验分享：提交10天，显示状态为Decision made什么情况？

42 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2023-05-18 36192448 来自湖南省

偏重的研究方向：细胞死亡
经验分享：一审65天了，还没消息，彻底躺平了

78 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2023-07-07 36192448 来自湖南省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：干细胞;细胞死亡
经验分享：一审84天，二审7天，目前decision made 7天还没消息

80 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2022-07-12 ms9000001463682571

4月12投稿
4月13检查格式通过
4月20指定责编
4月23送外审
4月25有审稿人同意审稿
5月4号审稿结束，开始决定意见
5月16日发邮件告知修回意见
7月7日修回
7月8日核对格式
7月9日决定意见
7月11日原则性接收，核对格式
7月12日正式接收

208 22

展开22条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2024-02-06 ms3000001660419742 来自台湾省

偏重的研究方向：幹細胞
经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ

30 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2023-07-01 Shawnwang 来自广东省

偏重的研究方向：细胞死亡
经验分享：刚刚submit，上帝保佑，沾沾大家的喜气

133 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2196205, encodeId=f8ea2196205f2, content=偏重的研究方向：免疫;细胞死亡 经验分享：我的Under Consideration 6天就直接Decision Made，这种情况是被拒了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a5603215, createdName=ms3000002118315862, createdTime=Sat Mar 30 11:00:33 CST 2024, time=2024-03-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2108140, encodeId=f9532108140cb, content=投稿7天 decision made ，现在12天了，not assigned，未收到邮件，是不是拒了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5285325183, createdName=148b8e1fm60暂无昵称, createdTime=Fri Dec 30 13:11:59 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154519, encodeId=b2e0215451923, content=从大CDD转投过来，转投之后状态一直是under consideration，目前16天，一直未分配编辑，请问大家都是多久分配编辑的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epGdmn7NtvEQpl9geHeaOsibJEgnfSKjJvhowzSCutQO1iavFpmdSmYR2mE5XcfcGdC4C1Oj56GJbgg/132, createdBy=a0bb2481042, createdName=1245a556m23暂无昵称, createdTime=Fri Aug 25 12:13:52 CST 2023, time=2023-08-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向：肿瘤 经验分享：提交10天，显示状态为Decision made什么情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2137379, encodeId=e314213e379f2, content=偏重的研究方向：细胞死亡 经验分享：一审65天了，还没消息，彻底躺平了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Thu May 18 09:01:28 CST 2023, time=2023-05-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;细胞死亡 经验分享：一审84天，二审7天，目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1232098, encodeId=5c09123209836, content=4月12投稿 4月13检查格式通过 4月20指定责编 4月23送外审 4月25有审稿人同意审稿 5月4号审稿结束，开始决定意见 5月16日发邮件告知修回意见 7月7日修回 7月8日核对格式 7月9日决定意见 7月11日原则性接收，核对格式 7月12日正式接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e4d6459453, createdName=ms9000001463682571, createdTime=Tue Jul 12 21:18:58 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向：幹細胞 经验分享：1/11 投稿還沒有editor assigned，祝大家投稿順利來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向：细胞死亡 经验分享：刚刚submit，上帝保佑，沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省)]

2024-03-05 超超不吵吵来自湖南省

投了一篇综述，一直是Under Consideration，在第22天左右分配了编辑，然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ，等待中。

19 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务